Illumina, Inc. vs Meta Platforms Inc — how do they compare? Illumina, Inc. trades at $268.5 (market cap $39.95B), while Meta Platforms Inc trades at $719.45 (market cap $1.84T). The key difference: Meta Platforms Inc is far larger — about 46.1× Illumina, Inc.'s market cap, and Meta Platforms Inc pays a 0.29% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Meta Platforms Inc for 127 Days on average.
| ILMN | META | |
|---|---|---|
Market Cap | $39.95B | $1.84T |
Volume | 3,169,503 | 15,887,049 |
Sector | Health | Media |
52-Week High | $293.69 | $777.59 |
52-Week Low | $91.00 | $525.72 |
Typical Hold Time | 83 Days | 127 Days |
Enterprise Value | $41.31B | $1.86T |
Dividend Yield | — | 0.29% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
META stock trades at $721.31, down 2.38% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish trend per moving averages, with key support at $719 and resistance at $726. Recent financials reveal strong revenue growth to $201.0B in 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. The launch of the Muse Spark AI model and a $21B deal with CoreWeave highlight strategic initiatives driving investor optimism, countered by ongoing legal challenges over youth addiction.
The outlook for META remains positive with an 80% analyst buy rating and a consensus price target of $781, suggesting ~8% upside. Key opportunities include AI monetization and robust cash flow growth, while risks involve regulatory lawsuits and high capital expenditures. Investors should weigh strong profitability against legal and competitive pressures in the social media sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →